The Republic of Moldova receives life-saving medicines for treating children with cancer through a recent international partnership designed to eliminate the “postal code lottery” that often determines a child’s survival based on where they are born.
The first shipment of essential oncology drugs arrived recently as part of the Global Platform for Access to Childhood Cancer Medicines. This joint initiative, established by the World Health Organization (WHO) and the St. Jude Children’s Research Hospital, aims to provide a consistent, uninterrupted supply of high-quality medications to low- and middle-income countries.
For the families in Moldova, This represents more than a logistical victory. It represents a systemic shift in how the country manages pediatric oncology, moving away from sporadic procurement toward a stable, international framework of supply and monitoring.
The medications were procured via the UNICEF Supply Division in Copenhagen, Denmark, and will be distributed to the pediatric oncology and hematology departments of the Institute of Oncology. As the only hospital in the country with a dedicated unit for children with cancer, the Institute serves as the primary lifeline for every child facing a diagnosis in Moldova.
Closing the Survival Gap
The urgency of this delivery is underscored by a stark disparity in survival outcomes. In high-income countries, the five-year survival rate for pediatric cancer often exceeds 80%. In the Republic of Moldova, that figure is approximately 60%.
Even as the 60% rate reflects steady improvement in national care, the gap remains a critical public health challenge. Each year, roughly 100 new cases of childhood cancer are diagnosed in the country. Recent data indicates that acute leukaemia is the most frequent diagnosis, followed by brain tumours.
In pediatric oncology, the window for effective intervention is narrow. Any interruption in the chemotherapy cycle or the use of sub-standard medications can lead to disease progression or the development of drug resistance.
“In paediatric oncology, time matters. Any interruption can influence the evolution of the disease, but also the families’ confidence in our ability to be with them,” said Dr. Emil Ceban, Minister of Health of the Republic of Moldova.
A New Framework for Pharmaceutical Access
Moldova became the second country in the WHO European Region to join the Global Platform in June 2023. The accession was based on the government’s demonstrated commitment to the WHO’s Global Initiative for Childhood Cancer and the implementation of the National Cancer Control Programme (2016–2025).
Unlike traditional aid shipments, the Global Platform is designed to shape the global market for pediatric cancer drugs. By consolidating demand from multiple countries, the platform can negotiate better prices and ensure that manufacturers produce the specific formulations needed for children, which are often overlooked in favor of adult medications.
Maha Damaj, UNICEF’s Representative in the Republic of Moldova, emphasized that the Copenhagen-based procurement process ensures transparency and international compliance, ensuring that every dose delivered is safe and effective.
The Global Reach of the Platform
The initiative is currently scaling to meet a massive unmet need. The goal is to provide an uninterrupted supply of quality-assured medicines to approximately 120,000 children across low- and middle-income countries over the next five to seven years.
| Region | Participating Countries |
|---|---|
| Europe/Asia | Republic of Moldova, Mongolia, Nepal, Pakistan, Uzbekistan |
| Americas | Ecuador, El Salvador |
| Africa | Ghana, Senegal, Zambia |
| Middle East | Jordan, Sri Lanka |
The platform provides end-to-end support, assisting nations not only with the physical delivery of drugs but also with the development of treatment standards and the creation of information systems to track patient outcomes.
Systemic Impact and Next Steps
The arrival of these medicines is a milestone in a broader effort to strengthen Moldova’s healthcare infrastructure. By integrating with the Global Platform, the Ministry of Health is adopting international standards for traceability and monitoring, which reduces the risk of medicine shortages and ensures that the right drug reaches the right child at the right time.
Dr. Rodriguez-Galindo, Executive Vice-President of St. Jude Children’s Research Hospital, noted that such collaborations bring the world closer to a future where a child’s survival is not determined by their geography.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for medical concerns or treatment options.
The next phase of the program will focus on the continued scaling of supplies and the further integration of the National Cancer Control Programme’s goals as it approaches its 2025 target date.
We invite readers to share this story and leave their thoughts in the comments below on how international partnerships can better address global health inequities.
